STXS
Stereotaxis, Inc. Common Stock
NYSE American · usd
Stereotaxis, Inc. Common Stock (STXS) trades at $0.9461 (+7.25%) as of 8:00:00 PM EST on Nov 18, 2026, -5.23% over the past month. Market cap is $95.42M, with 8.4 days to cover in short interest.
Stock performance
How Stereotaxis, Inc. Common Stock (STXS) stock has performed from one day to one year, with its 52-week range.
- 1D
- +7.26%
- 1W
- +5.12%
- 1M
- -5.23%
- YTD
- -58.87%
- 1Y
- -57.76%
- 52-wk range
- $0.80 – $2.86
Key statistics
Today's trading snapshot for STXS: day range, open, previous close, volume and market cap.
- Day range
- $0.87 – $0.95
- Open
- $0.89
- Prev close
- $0.88
- Volume
- 901.52K
- Market cap
- $95.42M
- Shares out
- 100.2M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Stereotaxis, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- 3.04
- P/B
- 3.61
- P/FCF
- —
- ROE
- -89.0%
- ROA
- -28.7%
- Debt/Equity
- 0.09
- Div yield
- 0.00%
As of Nov 18, 2026
8-K filings
Material corporate events Stereotaxis, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Debt issuanceNov 10, 2026
On November 9, 2026, Stereotaxis, Inc., a Delaware corporation (the "Company"), entered into a Note Purchase Agreement (the "Purchase Agreement") with certain accredited investors, including entities affiliated with certain members of our board of directors (the "Investors"), pursuant to which the Company agreed to issue and sell to the Investors, and the Investor agreed to purchase from the Company, convertible promissory notes issued by the Company (each, a "Note" and collectively, the "Notes") in the aggregate original principal amount of up to $24.0 million (such financing, the "Note Financing") consisting of (i) Notes in the aggregate original principal amount of $12.0 million (the "Initial Notes") and (ii) additional Notes in the aggregate original principal amount of up to $12.0 million (the "Additional Notes"), subject to the satisfaction or waiver of the conditions set forth therein.
- Acquisition completionJul 16, 2026
on July 7, 2026, Stereotaxis, Inc. (the "Company") completed its acquisition (the "Acquisition") of shares and other securities collectively representing 100% of the share capital and voting power of Robocath, a French société par actions simplifiée, pursuant to that certain Share Sale Agreement, dated as of April 14, 2026
- Acquisition consideration sharesJul 9, 2026
In connection with the Acquisition, the Company issued (i) 1,469,485 shares of its common stock, par value $0.001 per share (the "Common Stock") and (ii) "pre-funded" warrants (the "Purchaser Warrants") to purchase 4,575,143 shares of Common Stock to the securityholders of Robocath, in accordance with the terms and subject to the conditions set forth in the Share Sale Agreement.
- Acquisition agreementApr 15, 2026
On April 14, 2026, Stereotaxis, Inc. entered into a Share Sale Agreement with Robocath to acquire shares and other securities collectively representing 100% of the share capital and voting power of Robocath. The Company agreed to pay initial consideration of $20.0 million in cash and/or shares, plus additional earnout payments of up to $25 million if certain performance targets are met.
- Underwriting agreementAug 29, 2025
Roth Capital will be paid a placement fee of up to 3.0% of the gross sales price of the of the Shares sold pursuant the Sales Agreement. In addition, the Company has agreed to reimburse Roth Capital for certain specified expenses, including the fees and disbursements of its counsel in an amount not to exceed $50,000, in addition to certain ongoing disbursements not to exceed $5,000 per calendar quarter during any quarter in which sales pursuant to the Sales Agreement are made.
Dividend history and stock splits
Stereotaxis, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
No recent dividends.
Splits
- 5-for-4Sep 15, 2015
- 1-for-10Jul 11, 2012
STXS short interest
How heavily STXS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 8.4
- Short interest
- 5.56M
- Avg volume
- 661.22K
As of · reported to FINRA twice monthly.
STXS news
The latest news and headlines about Stereotaxis, Inc. Common Stock (STXS).
- ISRG Is Expanding Beyond Surgery: Here's Why the GI Opportunity MatterspositiveZacks Investment Research· Oct 13, 2026
- Stereotaxis Eyes Billions In Market Opportunity With Robocath TakeoverpositiveBenzinga· Apr 15, 2026
- Stereotaxis to Report Fourth Quarter and Full Year 2025 Financial Results on March 9, 2026neutralGlobeNewswire Inc.· Feb 12, 2026
- Stereotaxis to Report Third Quarter 2025 Financial Results on November 11, 2025neutralGlobeNewswire Inc.· Oct 21, 2025
- Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025positiveGlobeNewswire Inc.· Apr 22, 2025
Frequently asked questions
What is the Stereotaxis, Inc. Common Stock (STXS) stock price today?
Stereotaxis, Inc. Common Stock (STXS) is trading at $0.9461 (+7.25% on the day) as of 8:00:00 PM EST on Nov 18, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is Stereotaxis, Inc. Common Stock?
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the…
What is the short interest in STXS?
As of Oct 30, 2026, STXS has 5.56M shares short and 8.4 days to cover.
What exchange is STXS listed on?
Stereotaxis, Inc. Common Stock (STXS) trades on NYSE American in USD, in the ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry.
Build with AI
Build an analysis of STXS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a STXS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.